Serologicals has completed its previously announced acquisition of Cytomyx, a wholly owned subsidiary of Cytomyx Holdings
Based in Cambridge, UK, Cytomyx is a provider of ion channel cell lines and drug discovery services.
With 23 distinct ion channel cell lines commercially available, and more in its pipeline, Cytomyx offers the largest portfolio of distinct ion channel cell lines in the marketplace today.
Serologicals paid US$7 million for the stock of Cytomyx.
"We are very pleased to announce the completion of the Cytomyx acquisition," said David Dodd, president and CEO of Serologicals.
"Ion channels represent the third largest target class for Biopharma research and drug development today".
"The expertise that Cytomyx brings will greatly enhance our drug discovery products and services portfolio with therapeutically relevant ion channel cell lines and ion channel screening services".
"With GPCRs, kinases, and ion channels, Serologicals will better serve the needs of our Biopharma customers through a comprehensive portfolio offering."
